The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Much Larger Will The Ribonucleic Acid Interference (RNAi) Technology Market Become By 2030 Compared To 2026?
The ribonucleic acid interference (rnai) technology market has experienced rapid growth in recent years. Its value is expected to rise from $4.43 billion in 2025 to $5.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.9%. The expansion observed historically can be attributed to advancements in molecular biology research, early clinical successes of rnai therapeutics, the broadening of academic gene research programs, the availability of robust screening libraries, and the development of biotech innovation ecosystems.
The ribonucleic acid interference (rnai) technology market is anticipated to show significant expansion in the next few years. It is forecast to grow to $9.19 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. This growth during the forecast period is attributable to the increasing market presence of rnai-based drugs, a rise in funding for rare disease therapeutics, the advancement of nanoparticle delivery technologies, growing pharmaceutical sector collaborations, and greater regulatory acceptance for gene-silencing treatments. Prominent trends expected in this period include the wider adoption of gene silencing therapies, an increase in the use of sirna-based drug platforms, the growing integration of rnai into precision medicine, the expansion of treatments for targeted genetic diseases, and enhanced delivery system optimization.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30371&type=smp
What Primary Factors Are Fueling The Expansion Of The Ribonucleic Acid Interference (RNAi) Technology Market?
The ribonucleic acid interference (RNAi) technology market is anticipated to expand due to the escalating need for targeted therapeutics. These therapies are designed to specifically address and block molecular irregularities found in cancer and other illnesses, thereby enhancing treatment accuracy and reducing damage to healthy cells. The growing emphasis on targeted treatments stems mainly from progress in precision medicine, which facilitates tailored and more potent therapies aligned with unique genetic profiles. Ribonucleic Acid Interference (RNAi) Technology bolsters the demand for targeted therapeutics by allowing for exact gene silencing, crucial for addressing genetic and rare conditions. This technology aids in creating highly specific and efficacious treatments, thereby stimulating innovation within personalized medicine. An illustrative example is that in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, reported that the Food and Drug Administration (FDA) authorized 6 gene therapy products in 2023, an increase from 5 approvals in 2022. Consequently, the escalating need for targeted therapeutics is propelling the expansion of the ribonucleic acid interference (RNAi) technology market.
What Segment Types Are Included In The Ribonucleic Acid Interference (RNAi) Technology Market Analysis?
The ribonucleic acid interference (rnai) technology market covered in this report is segmented –
1) By Product: Micro Ribonucleic Acid (miRNA), Small Interfering Ribonucleic Acid (siRNA), Other Products
2) By Delivery Method: Viral Vectors, Nanoparticles, Chemical Modifications, Physical Methods
3) By Application: Therapeutics, Drug Discovery, Agriculture, Diagnostics
4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs) And Contract Manufacturing Organizations (CMOs)
Subsegments:
1) By Micro Ribonucleic Acid (miRNA): Micro Ribonucleic Acid Mimics, Micro Ribonucleic Acid Inhibitors, Micro Ribonucleic Acid Expression Vectors, Micro Ribonucleic Acid Profiling And Quantification Kits
2) By Small Interfering Ribonucleic Acid (siRNA): Small Interfering Ribonucleic Acid Synthetic Duplexes, Small Interfering Ribonucleic Acid Dicer Substrate Molecules, Small Interfering Ribonucleic Acid Self Delivering Conjugates, Small Interfering Ribonucleic Acid N Acetylgalactosamine Conjugates
3) By Other Products: Short Hairpin Ribonucleic Acid Expression Constructs, Ribonucleic Acid Interference Screening Libraries, Ribonucleic Acid Interference Transfection Reagents, Micro Ribonucleic Acid And Small Interfering Ribonucleic Acid Research Kits
Which Trends Are Influencing The Direction Of The Ribonucleic Acid Interference (RNAi) Technology Market?
Major companies engaged in the ribonucleic acid interference (RNAi) technology market are concentrating on integrating platforms, including strategic financing and assistance, to optimize the development, distribution, and market entry of RNA interference (RNAi) therapeutics. This approach allows for a consistent flow of multiple programs spanning various disease categories. Strategic funding and support refer to obtaining capital and resources from venture capital, industry collaborators, and other interested parties to accelerate the research, development, and commercialization of RNA interference (RNAi) therapeutics. For instance, in October 2024, City Therapeutics Inc., a US-based biopharmaceutical company, secured $135 million in Series A financing led by ARCH Venture Partners, with contributions from other leading life sciences investors, to pioneer the future of RNA interference (RNAi)-based medicine. This capital will be used to develop RNAi-based medicine by leveraging its exclusive lipid nanoparticle (LNP) delivery platform, which is designed for highly precise targeting of tissues beyond the liver. The platform aims to resolve a significant past constraint in the field, making possible the creation of treatments for a wider array of genetic disorders.
Who Are The Leading Firms Participating In The Ribonucleic Acid Interference (RNAi) Technology Market?
Major companies operating in the ribonucleic acid interference (rnai) technology market are F. Hoffmann-La Roche AG, Merck KGaA, Novartis AG, Thermo Fisher Scientific Inc., Danaher Corporation, Revvity Inc., QIAGEN N.V., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., GenScript Biotech Corporation, Promega Corporation, Arrowhead Pharmaceuticals Inc., Silence Therapeutics plc, Creative Biolabs Inc., Bioneer Corporation, Genevant Sciences Ltd., Gradalis Inc., Altogen Labs LLC, Sirnaomics Inc., Altogen Biosystems Inc.
Access The Complete Ribonucleic Acid Interference (RNAi) Technology Market Report:
What Is The Largest Regional Market In The Ribonucleic Acid Interference (RNAi) Technology Market?
North America was the largest region in the ribonucleic acid interference (RNAi) technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid interference (rnai) technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Ribonucleic Acid Interference (RNAi) Technology Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=30371&type=smp
Browse Through More Reports Similar to the Global Ribonucleic Acid Interference (RNAi) Technology Market 2026, By The Business Research Company
Ribonucleic Acid Rna Sequencing Market Report 2026
Nucleic Acid Isolation And Purification Market Report 2026
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model